Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome.
10.3760/cma.j.issn.1003-9406.2019.10.001
- Author:
Xuyan ZHOU
1
;
He JIN
;
Qitian MU
;
Lixia SHENG
;
Binbin LAI
;
Huiling ZHU
;
Guifang OUYANG
Author Information
1. The First Affiliated Hospital of Medical School of Ningbo University, Zhejiang, 315211. nbougf@163.com.
- Publication Type:Journal Article
- MeSH:
DNA Mutational Analysis;
Humans;
Incidence;
Mutation;
Myelodysplastic Syndromes;
genetics;
Prognosis;
Tumor Suppressor Protein p53;
genetics
- From:
Chinese Journal of Medical Genetics
2019;36(10):953-956
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the correlation of genetic mutations and clinical features of myelodysplastic syndromes (MDS) with scores of Revised International Prognostic Scoring System (IPSS-R).
METHODS:Eighty-seven patients with de novo MDS were enrolled. Mutations of MDS-related genes and clinical features were used to determine the incidence and subtype of mutations. Clinical features and IPSS-R scores of the patients with high frequency mutations involving TET2, TP53, ASXL1, RUNX1 and SF3B1 genes were compared.
RESULTS:Fifty-four patients (62.1%) harbored at least one point mutation. The incidences of various mutations were significantly different, with the incidence of MDS-EB-2 being 100% and MDS-SLD being only 38.9%. Compared with the wild types, patients harboring mutations had higher lactate dehydrogenase, higher β2 microglobulin, higher percentage of bone marrow blast cells and lower hemoglobin levels (P=0.027, <0.01, <0.01, 0.046, respectively). The IPSS-R scores of MDS patients with mutations were significantly higher than the wild types (P<0.01). The IPSS-R scores of the TP53 mutation groups were 7.82±1.83, which was significantly higher than the control group (3.77±1.66, P<0.01). No difference was found between the IPSS-R between patients carrying TET2, ASXL1, RUNX1, and SF3B1 mutations or the wild types (P>0.05).
CONCLUSION:Genetic mutations are commonly found in MDS. MDS patients with mutations have unique clinical laboratory characteristics. Although the prognostic value of most genes is controversial, TP53 is an definite indicator of poor prognosis.
